How to buy Lumos Pharma stock (LUMO)

Lumos Pharma is a biotechnology business based in the US. Lumos Pharma shares (LUMO) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $4.40 – an increase of 17.96% over the previous week. Lumos Pharma employs 33 staff and has a trailing 12-month revenue of around $1.5 million.

Our top picks for where to buy Lumos Pharma stock

Buy Lumos Pharma stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Paid non-client promotion. Finder does not invest money with providers on this page. If a brand is a referral partner, we're paid when you click or tap through to, open an account with or provide your contact information to the provider. Partnerships are not a recommendation for you to invest with any one company. Learn more about how we make money.

Finder is not an advisor or brokerage service. Information on this page is for educational purposes only and not a recommendation to invest with any one company, trade specific stocks or fund specific investments. All editorial opinions are our own.

Lumos Pharma stock price (NASDAQ: LUMO)

Use our graph to track the performance of LUMO stocks over time.

Lumos Pharma shares at a glance

• Key figures

Information last updated 2024-10-25.

Latest market close	$4.40
52-week range	$1.37 - $4.58
50-day moving average more info button	$3.75
200-day moving average more info button	$2.86
Wall St. target price	$15.63
PE ratio more info button	N/A
Dividend yield more info button	N/A
Earnings per share (TTM) more info button	$-4.42

Is it a good time to buy Lumos Pharma stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Lumos Pharma price performance over time

Historical closes compared with the close of $4.4 from 2024-10-25

1 week (2024-10-22)	11.39%
1 month (2024-09-27)	11.68%
3 months (2024-07-29)	150.00%
6 months (2024-04-29)	55.48%

1 year (2023-10-27)	16.71%
2 years (2022-10-28)	-51.89%
3 years (2021-10-29)	9.4
5 years (2019-10-29)	13.68

Lumos Pharma financials

Revenue TTM	$1.5 million
Gross profit TTM	$1.5 million
Return on assets TTM	-60.5%
Return on equity TTM	-132.56%
Profit margin	0%
Book value	$1.27
Market Capitalization more info button	$35.3 million

TTM: trailing 12 months

Lumos Pharma share dividends

We're not expecting Lumos Pharma to pay a dividend over the next 12 months.

Have Lumos Pharma's shares ever split?

Lumos Pharma's shares were split on a 1:9 basis on 18 March 2020 . So if you had owned 9 shares the day before before the split, the next day you'd have owned 1 share. This wouldn't directly have changed the overall worth of your Lumos Pharma shares – just the quantity. However, indirectly, the new 800% higher share price could have impacted the market appetite for Lumos Pharma shares which in turn could have impacted Lumos Pharma's share price.

Lumos Pharma share price volatility

Over the last 12 months, Lumos Pharma's shares have ranged in value from as little as $1.3701 up to $4.5756. A popular way to gauge a stock's volatility is its "beta".

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Lumos Pharma's is 0.358. This would suggest that Lumos Pharma's shares are less volatile than average (for this exchange).

Lumos Pharma overview

Lumos Pharma, Inc. , a clinical-stage biopharmaceutical company, focuses on the identification, acquisition, development, and commercialization of products and therapies for people with rare diseases. Its primary product candidate is LUM-201, an oral growth hormone secretagogue ibutamoren, which is in Phase III clinical trial for the treatment of idiopathic pediatric growth hormone deficiency and other rare endocrine disorders. The company has a clinical collaboration with Massachusetts General Hospital to evaluate oral LUM-201 in nonalcoholic fatty liver disease. Lumos Pharma, Inc. is headquartered in Austin, Texas. .

Frequently asked questions

What percentage of Lumos Pharma is owned by insiders or institutions?
Currently 34.805% of Lumos Pharma shares are held by insiders and 34.165% by institutions. How many people work for Lumos Pharma?
Latest data suggests 33 work at Lumos Pharma. When does the fiscal year end for Lumos Pharma?
Lumos Pharma's fiscal year ends in December. Where is Lumos Pharma based?
Lumos Pharma's address is: 4200 Marathon Boulevard, Austin, TX, United States, 78756 What is Lumos Pharma's ISIN number?
Lumos Pharma's international securities identification number is: US55028X1090 What is Lumos Pharma's CUSIP number?
Lumos Pharma's Committee on Uniform Securities Identification Procedures number is: 55028X109